AlloBMT indicates allogeneic bone marrow transplantation; AutoPBSCT, autologous peripheral blood stem cell transplantation; NA, not analyzed; and STAT, signal transducer and activator of transcription proteins.

High-dose cytarabine 3 g/m² every 12 hours for a total of 12 doses (1.5 g/m² for patients older than 50) and idarubicin 12 mg/m² daily for 3 consecutive days.

Five patients treated with cytarabine 100 mg/m² continuous infusion over 7 days, daunorubicin 60 mg/m² daily for 3 days, etoposide 100 mg/m² for 3 days; three patients treated with cytarabine 100 mg/m²continuous infusion over 7 days, daunorubicin 45 mg/m²daily for 3 days, etoposide 100 mg/m² for 3 days, and PSC 833 10 mg/m² for 3 days; one patient treated with cytarabine 200 mg/m² continuous infusion over 7 days and daunorubicin 45 mg/m² daily for 3 days; one patient treated with all-trans retinoic acid 40 mg/m² every 12 hours and idarubicin 12 mg/m² every other day for 4 doses; one patient treated with cytarabine 1.5 g/m² every 12 hours for a total of 12 doses; one patient treated with cytarabine 100 mg/m² continuous infusion over 7 days.

Etoposide 3.6 g/m² by continuous infusion and cyclophosphamide 50 mg/kg for 4 days.

High-dose cytarabine 2 g/m² every 12 hours for a total of 8 doses and daunorubicin 45 mg/m² for 2 days.

Cytarabine 100 mg/m² continuous infusion over 5 days, daunorubicin 60 mg/m² daily for 2 days, and etoposide 100 mg/m² for 2 days.

Cytarabine 100 mg/m² continuous infusion over 7 days and daunorubicin 45 mg/m² daily for 3 days.